Trump Prepares to Invoke Emergency Law to Ease Sable Offshore Permitting
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.Trump to invoke emergency law to ease Sable Offshore permitting, Bloomberg saysEMERGENCY LAW:In a "long-shot bid" to help ease the global crude supply crunch spurred by his war with Iran, President Donald Trump is preparing to invoke the Defense Production Act to preempt state laws and ease permitting for Sable Offshore, which is looking to restart significant oil production from a cluster of offshore platforms in California, reported Bloomberg's Jennifer Dlouhy and Nathan Risser.STRAIT OF HORMUZ:In the first public comments from Iran's new Supreme Leader Mojtaba Khamenei since he was appointed on March 9 after the assassination of his father, Khamenei has said all U.S. military bases in the Middle East should close immediately as those bases will be attacked. The closure of the Strait of Hormuz maritime passage should be continued as a "tool to pressure the enemy," he said in televised comments, according to a translation by Reuters. "Iran will not refrain from avenging the blood of its martyrs," Khamenei is quoted as having said.Meanwhile, Ebrahim Zolfaqari, spokesperson for Iran's military command, said the world should "Get ready for oil to be $200 a barrel, because the oil price depends on regional security, which you have destabilised," Reuters' Parisa Hafezi and Alexander Cornwell. The total number of merchant ships that have been hit since the war began has now risen to 14, the report states.SECTION 301 TARIFF INVESTIGATIONS:The Trump administration is preparing to announce new tariff investigations as soon as Wednesday will be initiated under Section 301 of the Trade Act of 1974, which allows the president to levy tariffs against nations that discriminate against U.S. firms or commerce,The Wall Street Journal's Gavin Bade. The Section 301 tariffs are designed to replace the temporary global duties of 10% that Trump imposed last month after the Supreme Court ruled many of his second-term levies illegal, the report noted.THERMO FISHER VISIT:In a Truth Social post, President Trump, "I am on my way to the Great State of Ohio, which I love and WON BIG three times, to visit Thermo Fisher, a Pharmaceutical Manufacturing Company, that is investing $2 Billion Dollars in U.S. Manufacturing, and bringing GREAT paying jobs back to Ohio from overseas. Thermo Fisher is doing this because of my America First Trade Policies, most specifically TARIFFS, which charge other Countries for access to our Markets while protecting our important Industries, and strengthening our Supply Chains. Thanks to my 'Most Favored Nation' Deals, Prescription Drug Prices are coming down by A LOT, and I have asked Congress to CODIFY these Policies. After that I will be heading to the wonderful Commonwealth of Kentucky. See you soon!"
Trade with 70% Backtested Accuracy
Analyst Views on TMO
About TMO
About the author
The Overlooked Sector of Healthcare That Has Captivated Wall Street
Health Care Industry Volatility: The health care sector is characterized by significant volatility, with companies experiencing drastic changes in stock prices based on the success of individual products or clinical trials.
Investment Trends: Investors are increasingly focusing on companies that provide essential equipment and services rather than high-risk pharmaceutical names, despite some major players in the lab equipment sector being overlooked.
Thermo Fisher's Performance: Thermo Fisher Scientific has faced challenges in 2026, with shares dropping over 15% year-to-date, but recent revenue growth and strong earnings suggest potential for recovery.
Agilent's Growth Potential: Agilent Technologies is expected to see significant growth in earnings and share price, driven by its recent acquisition of BioCare Medical, which enhances its capabilities in cancer diagnostics.
THERMO FISHER SCIENTIFIC FINALIZES PURCHASE OF CLARIO HOLDINGS, INC.
Acquisition Announcement: The Thermo Fisher Scientific has completed the acquisition of Clario Holdings, Inc.
Strategic Importance: This acquisition is expected to enhance Thermo Fisher's capabilities in the life sciences sector.
High Options Volume for New York Times and Thermo Fisher Scientific
- New York Times Options: New York Times (NYT) options volume reached 22,095 contracts today, representing approximately 2.2 million shares, which constitutes 98.3% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- High Volume Put Options: Within NYT, the $80 strike put option saw 10,001 contracts traded today, representing about 1.0 million shares, reflecting investor expectations of potential price declines, which could impact stock volatility.
- Thermo Fisher Options: Thermo Fisher Scientific Inc (TMO) options volume reached 19,487 contracts today, equating to approximately 1.9 million shares, accounting for 94% of its average daily trading volume over the past month, showcasing active market interest in its stock.
- Put Option Concerns: For TMO, the $570 strike put option traded 2,100 contracts today, representing around 210,000 shares, indicating investor concerns about potential future declines, which may affect its market performance.
HSBC Downgrades Eli Lilly, Signals Cooling Obesity Drug Market
- Rating Downgrade: HSBC analysts downgraded Eli Lilly from Hold to Reduce, slashing the target price from $1,070 to $850, citing that the stock is currently 'priced to perfection' and faces significant competitive headwinds.
- Market Expectation Correction: Analysts argue that the total addressable market (TAM) for obesity drugs is overestimated, likely to be between $80 billion and $120 billion by 2032, rather than the consensus expectation of $150 billion, indicating that market demand may not be as robust as anticipated.
- Intensifying Competition: While Lilly's stock has risen 20% over the past year, significantly outperforming Novo Nordisk's 55% decline, analysts warn that as competitors like Novo push back in pricing, the battle for market share will intensify.
- Healthcare Sector Outlook: Despite caution on Lilly and the obesity drug market, HSBC remains bullish on the broader healthcare sector, viewing it as a safer investment amid AI disruption and geopolitical instability, and recommends focusing on AstraZeneca, AbbVie, and Johnson & Johnson for better risk-reward profiles.
Analysis of XLV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XLV ETF has a 52-week low of $127.35 and a high of $160.59, with the last trade at $153.55, indicating stability and potential investment appeal in the current market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with valuable insights for technical analysis, aiding in market trend assessment and timing of investments.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, allowing investors to capitalize on market dynamics and opportunities.
Baron Health Care Fund Reports Strong Q4 2025 Performance
- Quarterly Growth: For the quarter ending December 31, 2025, the Baron Health Care Fund increased by 13.10%, significantly outperforming the Russell 3000 Health Care Index's 11.92% and the Russell 3000 Index's 2.40%, indicating strong performance in the healthcare sector.
- Key Contributors: Companies such as Eli Lilly, Cidara Therapeutics, and Argenx SE were major contributors this quarter, reflecting ongoing momentum in GLP-1 therapies and innovation in biotechnology, which drove the fund's gains.
- Portfolio Adjustments: The fund added seven new positions and exited ten during the quarter, bringing the total number of positions to 43, demonstrating its agile investment strategy in response to market changes.
- Risk Management Actions: The fund reduced its positions in Stryker and Boston Scientific due to valuation concerns while also decreasing its stake in Arcellx to manage risks associated with increasing competition and regulatory challenges, showcasing its responsiveness to market dynamics.
The Overlooked Sector of Healthcare That Has Captivated Wall Street
Health Care Industry Volatility: The health care sector is characterized by significant volatility, with companies experiencing drastic changes in stock prices based on the success of individual products or clinical trials.
Investment Trends: Investors are increasingly focusing on companies that provide essential equipment and services rather than high-risk pharmaceutical names, despite some major players in the lab equipment sector being overlooked.
Thermo Fisher's Performance: Thermo Fisher Scientific has faced challenges in 2026, with shares dropping over 15% year-to-date, but recent revenue growth and strong earnings suggest potential for recovery.
Agilent's Growth Potential: Agilent Technologies is expected to see significant growth in earnings and share price, driven by its recent acquisition of BioCare Medical, which enhances its capabilities in cancer diagnostics.
THERMO FISHER SCIENTIFIC FINALIZES PURCHASE OF CLARIO HOLDINGS, INC.
Acquisition Announcement: The Thermo Fisher Scientific has completed the acquisition of Clario Holdings, Inc.
Strategic Importance: This acquisition is expected to enhance Thermo Fisher's capabilities in the life sciences sector.
High Options Volume for New York Times and Thermo Fisher Scientific
- New York Times Options: New York Times (NYT) options volume reached 22,095 contracts today, representing approximately 2.2 million shares, which constitutes 98.3% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- High Volume Put Options: Within NYT, the $80 strike put option saw 10,001 contracts traded today, representing about 1.0 million shares, reflecting investor expectations of potential price declines, which could impact stock volatility.
- Thermo Fisher Options: Thermo Fisher Scientific Inc (TMO) options volume reached 19,487 contracts today, equating to approximately 1.9 million shares, accounting for 94% of its average daily trading volume over the past month, showcasing active market interest in its stock.
- Put Option Concerns: For TMO, the $570 strike put option traded 2,100 contracts today, representing around 210,000 shares, indicating investor concerns about potential future declines, which may affect its market performance.
HSBC Downgrades Eli Lilly, Signals Cooling Obesity Drug Market
- Rating Downgrade: HSBC analysts downgraded Eli Lilly from Hold to Reduce, slashing the target price from $1,070 to $850, citing that the stock is currently 'priced to perfection' and faces significant competitive headwinds.
- Market Expectation Correction: Analysts argue that the total addressable market (TAM) for obesity drugs is overestimated, likely to be between $80 billion and $120 billion by 2032, rather than the consensus expectation of $150 billion, indicating that market demand may not be as robust as anticipated.
- Intensifying Competition: While Lilly's stock has risen 20% over the past year, significantly outperforming Novo Nordisk's 55% decline, analysts warn that as competitors like Novo push back in pricing, the battle for market share will intensify.
- Healthcare Sector Outlook: Despite caution on Lilly and the obesity drug market, HSBC remains bullish on the broader healthcare sector, viewing it as a safer investment amid AI disruption and geopolitical instability, and recommends focusing on AstraZeneca, AbbVie, and Johnson & Johnson for better risk-reward profiles.
Analysis of XLV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XLV ETF has a 52-week low of $127.35 and a high of $160.59, with the last trade at $153.55, indicating stability and potential investment appeal in the current market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with valuable insights for technical analysis, aiding in market trend assessment and timing of investments.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, allowing investors to capitalize on market dynamics and opportunities.
Baron Health Care Fund Reports Strong Q4 2025 Performance
- Quarterly Growth: For the quarter ending December 31, 2025, the Baron Health Care Fund increased by 13.10%, significantly outperforming the Russell 3000 Health Care Index's 11.92% and the Russell 3000 Index's 2.40%, indicating strong performance in the healthcare sector.
- Key Contributors: Companies such as Eli Lilly, Cidara Therapeutics, and Argenx SE were major contributors this quarter, reflecting ongoing momentum in GLP-1 therapies and innovation in biotechnology, which drove the fund's gains.
- Portfolio Adjustments: The fund added seven new positions and exited ten during the quarter, bringing the total number of positions to 43, demonstrating its agile investment strategy in response to market changes.
- Risk Management Actions: The fund reduced its positions in Stryker and Boston Scientific due to valuation concerns while also decreasing its stake in Arcellx to manage risks associated with increasing competition and regulatory challenges, showcasing its responsiveness to market dynamics.
